vs
Caris Life Sciences, Inc.（CAI）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Caris Life Sciences, Inc.的季度营收约是VERACYTE, INC.的1.5倍（$216.8M vs $140.6M）。VERACYTE, INC.净利率更高（29.3% vs 11.2%，领先18.0%）。Caris Life Sciences, Inc.同比增速更快（113.4% vs 18.5%）。Caris Life Sciences, Inc.自由现金流更多（$55.3M vs $48.8M）
Caris生命科学是一家领先的精准医疗生物技术企业，专注于肿瘤领域的先进分子检测服务，为肿瘤医生提供可落地的基因组与分子层面洞察以制定个性化癌症治疗方案，同时与生物制药企业合作加速抗癌新药研发，业务覆盖北美、欧洲及亚太主要市场。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
CAI vs VCYT — 直观对比
营收规模更大
CAI
是对方的1.5倍
$140.6M
营收增速更快
CAI
高出94.8%
18.5%
净利率更高
VCYT
高出18.0%
11.2%
自由现金流更多
CAI
多$6.5M
$48.8M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $216.8M | $140.6M |
| 净利润 | $24.3M | $41.1M |
| 毛利率 | — | 72.5% |
| 营业利润率 | 15.1% | 26.4% |
| 净利率 | 11.2% | 29.3% |
| 营收同比 | 113.4% | 18.5% |
| 净利润同比 | 135.9% | 704.8% |
| 每股收益（稀释后） | $0.08 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAIVCYT
| Q4 25 | — | $140.6M | ||
| Q3 25 | $216.8M | $131.9M | ||
| Q2 25 | $181.4M | $130.2M | ||
| Q1 25 | — | $114.5M | ||
| Q4 24 | — | $118.6M | ||
| Q3 24 | $101.6M | $115.9M | ||
| Q2 24 | $100.0M | $114.4M | ||
| Q1 24 | — | $96.8M |
净利润CAIVCYT
| Q4 25 | — | $41.1M | ||
| Q3 25 | $24.3M | $19.1M | ||
| Q2 25 | $-71.8M | $-980.0K | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $-67.7M | $15.2M | ||
| Q2 24 | $-66.2M | $5.7M | ||
| Q1 24 | — | $-1.9M |
毛利率CAIVCYT
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
营业利润率CAIVCYT
| Q4 25 | — | 26.4% | ||
| Q3 25 | 15.1% | 17.4% | ||
| Q2 25 | -9.9% | -4.0% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | -59.9% | 10.4% | ||
| Q2 24 | -67.0% | 4.0% | ||
| Q1 24 | — | -4.8% |
净利率CAIVCYT
| Q4 25 | — | 29.3% | ||
| Q3 25 | 11.2% | 14.5% | ||
| Q2 25 | -39.6% | -0.8% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | -66.6% | 13.1% | ||
| Q2 24 | -66.2% | 5.0% | ||
| Q1 24 | — | -1.9% |
每股收益（稀释后）CAIVCYT
| Q4 25 | — | $0.50 | ||
| Q3 25 | $0.08 | $0.24 | ||
| Q2 25 | $-7.97 | $-0.01 | ||
| Q1 25 | — | $0.09 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $-2.59 | $0.19 | ||
| Q2 24 | $-2.54 | $0.07 | ||
| Q1 24 | — | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $755.5M | $362.6M |
| 总债务越低越好 | $375.9M | — |
| 股东权益账面价值 | $478.4M | $1.3B |
| 总资产 | $984.6M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资CAIVCYT
| Q4 25 | — | $362.6M | ||
| Q3 25 | $755.5M | $315.6M | ||
| Q2 25 | $721.2M | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | — | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | — | $235.9M | ||
| Q1 24 | — | $209.2M |
总债务CAIVCYT
| Q4 25 | — | — | ||
| Q3 25 | $375.9M | — | ||
| Q2 25 | $373.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CAIVCYT
| Q4 25 | — | $1.3B | ||
| Q3 25 | $478.4M | $1.3B | ||
| Q2 25 | $452.9M | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $-2.4B | $1.2B | ||
| Q2 24 | $-2.4B | $1.1B | ||
| Q1 24 | — | $1.1B |
总资产CAIVCYT
| Q4 25 | — | $1.4B | ||
| Q3 25 | $984.6M | $1.4B | ||
| Q2 25 | $955.1M | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
负债/权益比CAIVCYT
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.4M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $55.3M | $48.8M |
| 自由现金流率自由现金流/营收 | 25.5% | 34.7% |
| 资本支出强度资本支出/营收 | 3.3% | 2.7% |
| 现金转化率经营现金流/净利润 | 2.57× | 1.28× |
| 过去12个月自由现金流最近4个季度 | — | $126.6M |
8季度趋势，按日历期对齐
经营现金流CAIVCYT
| Q4 25 | — | $52.6M | ||
| Q3 25 | $62.4M | $44.8M | ||
| Q2 25 | — | $33.6M | ||
| Q1 25 | — | $5.4M | ||
| Q4 24 | — | $24.5M | ||
| Q3 24 | — | $30.0M | ||
| Q2 24 | — | $29.6M | ||
| Q1 24 | — | $-9.0M |
自由现金流CAIVCYT
| Q4 25 | — | $48.8M | ||
| Q3 25 | $55.3M | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M | ||
| Q1 24 | — | $-11.1M |
自由现金流率CAIVCYT
| Q4 25 | — | 34.7% | ||
| Q3 25 | 25.5% | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% | ||
| Q1 24 | — | -11.5% |
资本支出强度CAIVCYT
| Q4 25 | — | 2.7% | ||
| Q3 25 | 3.3% | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 2.2% |
现金转化率CAIVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | 2.57× | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAI
| Molecular Profiling Services | $207.6M | 96% |
| Pharma Research And Development Services | $9.2M | 4% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
